Using blood tests to assess early treatment response in cancer patients
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
This study is testing if blood tests that look for cancer DNA can help doctors see how well treatment is working for patients with different types of solid tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT04354064 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of circulating tumor DNA (ctDNA) in detecting early treatment responses in patients with various solid tumors, including prostate, head and neck, esophageal, and genitourinary cancers. By identifying molecular residual disease (MRD) through ctDNA analysis, the study seeks to enhance cancer diagnosis, treatment, and surveillance, ultimately guiding clinical decision-making in personalized medicine. The findings could pave the way for future interventional trials that escalate therapy based on early ctDNA detection.
Who should consider this trial
Good fit: Ideal candidates for this study include healthy volunteers aged 18 and older, as well as patients diagnosed with the specified solid tumors.
Not a fit: Patients younger than 18 years old will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of cancer recurrence, providing patients with more treatment options and potentially improving outcomes.
How similar studies have performed: Other studies utilizing ctDNA for early detection and monitoring of cancer have shown promising results, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Eligible healthy donors will be at least 18 years of age. Exclusion Criteria: * Healthy donors younger than 18 years of age
Where this trial is running
St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Melissa Reimers, M.D. — Washington University School of Medicine
- Study coordinator: Melissa Reimers, M.D.
- Email: cbumb@wustl.edu
- Phone: 314-362-7249
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.